PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders.
| (a) |
Provectus Biopharmaceuticals, Inc. (the Company) held its annual meeting of stockholders on Tuesday, May30, 2017. |
| (b) |
At the 2017 annual meeting, the Companys stockholders voted on six proposals. A brief description and tabulation of votes for each proposal are set forth below. |
Proposal 1. The Companys stockholders elected
the following directors for a term of one year, consistent with
the recommendation of the Companys Board of Directors (the
Board). There were 155,379,803 broker non-votes with respect to
the proposal.
|
Nominee |
For | Withheld | ||
|
Bruce Horowitz |
114,749,847 | 12,563,928 | ||
|
Jan E. Koe |
113,862,809 | 13,450,966 | ||
|
Dominic Rodrigues |
116,728,417 | 10,585,358 | ||
|
Eric A. Wachter, Ph.D. |
111,570,360 | 15,743,415 |
Proposal 2. The Companys stockholders approved
the advisory vote on the compensation of the Companys named
executive officers, consistent with the Boards recommendation.
There were 155,379,803 broker non-votes with respect to the
proposal.
| For | Against | Abstain | ||
| 108,049,907 | 17,665,031 | 1,598,837 |
Proposal 3. The Companys stockholders expressed
their preference to conduct future advisory votes on executive
compensation every year, consistent with the Boards
recommendation. There were 155,379,803 broker non-votes with
respect to the proposal. This policy will remain in effect until
the next advisory stockholder vote as would be set forth in the
Companys proxy statement for its 2023 annual meeting.
| One Year | TwoYears | ThreeYears | Abstain | |||
| 116,841,564 | 3,721,040 | 4,789,375 | 1,961,796 |
Proposal 4. The Companys stockholders ratified
the selection of Marcum LLP as the Companys independent
registered public accounting firm for 2017, consistent with the
Boards recommendation. There were no broker non-votes with
respect to the proposal.
| For | Against | Abstain | ||
| 262,554,263 | 15,704,221 | 4,435,094 |
Proposal 5. The Companys stockholders did not
approve an amendment of the Certificate of Incorporation, as
amended, to increase the number of authorized shares of preferred
stock, as a majority of the outstanding shares of common stock
entitled to vote were required to vote in favor of this proposal
in order to approve it. There were 155,379,803 broker non-votes
with respect to the proposal.
| For | Against | Abstain | ||
| 102,632,187 | 23,924,913 | 756,675 |
Proposal 6. The Companys stockholders approved
an amendment of the Provectus 2014 Equity Compensation Plan to
allow for the grant of restricted stock awards, consistent with
the Boards recommendation. There were 155,379,803 broker
non-votes with respect to the proposal.
| For | Against | Abstain | ||
| 103,063,213 | 17,488,420 | 6,762,142 |
About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors. PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information
PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session up +0.0031 at 0.0466 with 674,508 shares trading hands.